PureWow editors select every item that appears on this page, and some items may be gifted to us. Additionally, PureWow may ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

While Audrey Hepburn remains one of the reigning Queens of Old Hollywood, an on-screen legend, she was also the proudest ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...

She takes a compounded version of tirzepatide, Eli Lilly's drug sold under the name Mounjaro to treat diabetes and Zepbound for weight loss. The average retail price for Zepbound is nearly $1,300 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

Feb 28 (Reuters) - Eli Lilly (LLY.N), opens new tab launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off ...

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

Eli Lilly (LLY), the maker of the blockbuster weight ... The campaign, titled “Healthy Skepticism,” will appear in print ads in select national newspapers and a video version is already ...